EGFR and non-small cell lung carcinoma: Afatinib and osimertinib are active in the treatment of patients with NSCLC who carry uncommon EGFR mutations, according to the observations of clinical trials and research conducted in the real world.8,9,12,13 However, given the low mutation frequency as well as high heterogeneity of uncommon EGFR mutations, there have been no clinical studies comparing the efficacies of afatinib and osimertinib in patients with NSCLC harboring uncommon EGFR mutations.